IDYA Key Statistics, Chart & Performance
The current stock price of IDYA is 33.99 USD. In the past month the price increased by 16.48%. In the past year, price increased by 26.88%.
IDYA Latest News, Press Relases and Analysis
IDYA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About IDYA
Company Profile
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Company Info
IDEAYA BIOSCIENCES INC
7000 Shoreline Ct, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Yujiro Hata
Employees: 131
Phone: 16504436209
IDEAYA BIOSCIENCES INC / IDYA FAQ
What does IDYA do?
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
What is the stock price of IDEAYA BIOSCIENCES INC today?
The current stock price of IDYA is 33.99 USD. The price increased by 2.5% in the last trading session.
What is the dividend status of IDEAYA BIOSCIENCES INC?
IDYA does not pay a dividend.
What is the ChartMill rating of IDEAYA BIOSCIENCES INC stock?
IDYA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for IDEAYA BIOSCIENCES INC?
IDEAYA BIOSCIENCES INC (IDYA) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of IDEAYA BIOSCIENCES INC (IDYA) based on its PE ratio?
IDEAYA BIOSCIENCES INC (IDYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).
Can you provide the short interest for IDYA stock?
The outstanding short interest for IDEAYA BIOSCIENCES INC (IDYA) is 9.06% of its float.
IDYA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IDYA. When comparing the yearly performance of all stocks, IDYA is one of the better performing stocks in the market, outperforming 91.02% of all stocks.
IDYA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IDYA. While IDYA has a great health rating, there are worries on its profitability.
IDYA Financial Highlights
Over the last trailing twelve months IDYA reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 20.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.52% | ||
| ROE | -14.67% | ||
| Debt/Equity | 0 |
IDYA Forecast & Estimates
25 analysts have analysed IDYA and the average price target is 49.22 USD. This implies a price increase of 44.79% is expected in the next year compared to the current price of 33.99.
For the next year, analysts expect an EPS growth of 3.78% and a revenue growth 192.96% for IDYA